Adam Feuerstein's Biotech Blog

Adam Feuerstein's Biotech Blog - TheStreet

Adam Feuerstein

Adam Feuerstein investigates the highly-speculative world of biotech stocks, and helps biotech investors avoid losing money.

To participate in Adam's "Biotech Stock Mailbag," please send your questions or comments using this form.

To chat with Adam on Twitter, click here.

Biotech Blog

Nektar plans to out-license the experimental opioid NKTR-181 to a partner for continued development.
3/20/17 7:30AM
Is Repatha's $14,000 price tag justified by the magnitude of the drug's benefit to patients, measured by a lower risk of heart attacks and strokes?
3/17/17 10:38AM
PTC Therapeutics already sells a drug for Duchenne muscular dystrophy that does not work. Now, the drug maker is buying a second, approved Duchenne drug mired in a price-gouging controversy.
3/16/17 10:54AM
AstraZeneca's PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo.
3/14/17 3:43PM
The deal announced Tuesday gives Allergan exclusive access to five Editas programs aimed at serious, inherited eye diseases.
3/14/17 9:59AM
Aurinia executives don't manage the business to serve the interest of traders and their desire to flip the stock for a few bucks' profit.
3/14/17 9:01AM
Despite all the prior failures and blowups, an Alzheimer's drug study -- no matter how unlikely to succeed -- remains an irresistible lure for some investors.
3/13/17 12:51PM
Gottlieb is the preferred FDA Commissioner pick of the drug industry and healthcare investors.
3/10/17 2:22PM
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
3/10/17 7:37AM
The firms all have drugs they want the feds to bend the rules to approve.
3/8/17 12:40PM
The convenience of a once-daily version of Kalydeco is important to Vertex because it has the potential to simplify dosing of combination regimens the company has in development.
3/6/17 7:01AM
The newly reconstituted Immunomedics board is likely to start a search for a new CEO and could either renegotiate the IMMU-132 deal with Seattle Genetics or cancel it.
3/3/17 12:21PM
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
3/3/17 7:33AM
The latest setback occurred in a phase III study of cystic fibrosis patients, where treatment with ataluren over 48 weeks failed to improve lung function compared to a placebo.
3/2/17 9:31AM
Roche shares surged in Zurich Thursday after the Swiss drugmaker said trials of its key breast cancer drug showed solid results when compared to chemotherapy.
3/2/17 6:36AM
Aurinia has designed a phase III study of voclosporin in lupus nephritis that aims to replicate the results observed in the phase II study.
3/1/17 4:05PM
Absent specific policy details, Trump's speech leaves investors guessing about his real plans for the FDA and the drug approval process. He has not yet named an FDA commissioner.
3/1/17 8:12AM
Kite intends to submit a marketing application for KTE-C19 to the U.S. Food and Drug Administration by the end of March.
2/28/17 8:01AM
Current drugs approved to prevent and reduce the frequency of HAE swelling attacks require injections, so BioCryst's once-daily pill has the potential to be more convenient.
2/27/17 10:02AM
The company intends to submit a marketing application for LJPC-501 to the FDA in the second half of the year, pending the outcome of a meeting with regulators.
2/27/17 8:10AM
Trevena intends to submit the new painkiller, known as oliceridine, for marketing approval with the U.S. Food and Drug Administration in the fourth quarter, the company said.
2/21/17 9:07AM
Ozanimod is part of Celgene's strategy to grow its inflammation and immunology business as a diversification hedge away from Revlimid, the blockbuster blood cancer drug.
2/17/17 8:39AM
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
2/17/17 7:44AM
Less than two years later, Alexion is not getting the bang for the mega-bucks it put up for Synageva.
2/16/17 10:38AM